高、低侵袭性肝癌干细胞模型的建立及生物学特性鉴定

Abstract
Figure/Table
References (0)
Related Citation (5)

Download: PDF (1571 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To establish high/low invasion liver cancer stem cells (H/L-ILCSCs) model from human liver cancer cell line HCCLM3, and compare their biological properties with HCCLM3 and HL-7702 cells. Methods: ①Transwell immigration assay was used to separate high/low immigration HCCLM3 cells, then the high/low invasion HCCLM3 cells were isolated from high/low immigration HCCLM3 cells by Transwell invasion assay. ②H/L-ILCSCs were isolated from CD133+ high/low invasion HCCLM3 cells using magnetic activated cell sorting. ③The expression of cancer stem cell markers CD133+, CD90+ and CD44+ were detected in H-ILCSCs, L-ILCSCs, HCCLM3 and HL-7702 cells. ④The proliferation, invasion, clonal sphere formation and tumorigenicity were investigated by CCK-8 assay, Transwell invasion assay, monoclonal sphere formation and transplanted tumor formation assay in nude mice in H-ILCSCs, L-ILCSCs, HCCLM3 and HL-7702 cells. Results: High expression levels of cancer stem cell markers CD133+, CD90+ and CD44+ in H-ILCSCs, but high expression levels of CD133+ and low expression levels of CD90+ and CD44+ in L-ILCSCs. The abilities of proliferation, invasion, clonal sphere formation and tumorigenicity in L-ILCSCs, HCCLM3 and HL-7702 cells were lower than in H-ILCSCs. The abilities of proliferation and invasion in L-ILCSCs were lower than in HCCLM3 cells. Besides, stem cell spheres and nude mouse transplanted tumor couldn’t be established in L-ILCSCs cells. Conclusion: H/L-ILCSCs can be isolated and expanded from HCCLM3 cells, and both cells exhibit distinct biological properties.

Key words： HL-7702 cells HCCLM3 cells invasion liver cancer stem cell biological properties

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Yuncheng
	ZENG Fang
	DING Xianjun
	LI Shibo

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2018/V48/I8/572

[1] LOBO N A, SHIMONO Y, QIAN D, et al. The biology of cancer stem cells[J]. Annu Rev Cell Dev Bio, 2007, 23(1): 675-699.
[2] GUGLIELMI A, RUZZENENTE A, CONCI S, et al. Hepatocellular carcinoma: Surgical perspectives beyond the barcelona clinic liver cancer recommendations[J]. World J Gastroenterol, 2014, 20(24): 7525-7533.
[3] SELL S, LEFFERT H L. Liver cancer stem cells[J]. J Clin Oncol, 2008, 26(17): 2800-2805.
[4] YAMASHITA T, JI J, BUDHU A, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features[J]. Gastroenterology, 2009, 136 (3): 1012-1024.
[5] 曾芳, 刘晓光, 乐涵波. 高/低侵袭转移性肺癌干细胞模型的建立[J]. 医学研究杂志, 2012, 41(7): 62-66.
[6] TIE J, PAN Y, ZHAO L, et al. MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the robo1 re-ceptor[J]. PLoS Genet, 2010, 6(3): e1000879.
[7] KALLURI R, NEILSON E G. Epithelial-mesenchymal transition and its implications for fibrosis[J]. J Clin Invest, 2003, 112(12): 1776-1784.
[8] MANI S A, GUO W, LIAO M J, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells[J]. Cell, 2008, 133(4): 704-715.
[9] TAKEBE N, WARREN R Q, IVY S P. Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition[J]. Breast Cancer Res, 2011, 13(3): 211.
[10] BAHNASSY A A, FAWZY M, EL-WAKIL M, et al. Aberrant expression of cancer stem cell markers (CD44, CD90 and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients:4-year survival data[J]. Transl Res, 2015, 165(3): 396-406.
[11] WRIGHT M H, CALCAGNO A M, SALCIDO C D, et al.
Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics[J]. Breast Cancer Res, 2008, 10(1): R10.
[12] BRABLETZ S, SCHMALHOFER O, BRABLETZ T. Gastrointestinal stem cells in development and cancer[J]. J Patholo, 2009, 217(2): 307-317.
[13] HERMANN P C, HUBER S L, HEESCHEN C. Metastatic cancer stem cells: a new target for anti-cancer therapy?[J]. Cell Cycle, 2008, 7(2): 188-193.
[14] VISVADER J E, LINDEMAN G J. Cancer stem cells in solid tumours: accumulating evidence and unresolved ques-tions[J]. Nat Rev Cancer, 2008, 8(10): 755-768.